GSK/$GSK
1D1W1MYTD1Y5YMAX
Capital at risk
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Ticker
- $GSK
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 66,841
- Headquarters
- London, United Kingdom
- Website
- www.gsk.com
GSK Metrics
BasicAdvanced
$101B
31.81
$1.58
0.29
$1.77
3.56%
Price and volume
Market cap
$101B
Beta
0.29
52-week high
$61.70
52-week low
$39.29
Average daily volume
2.9M
Dividend rate
$1.77
Financial strength
Current ratio
0.815
Quick ratio
0.519
Long term debt to equity
0.815
Total debt to equity
1.065
Dividend payout ratio (TTM)
55.30%
Interest coverage (TTM)
14.62%
Profitability
EBITDA (TTM)
14,491.793
Gross margin (TTM)
73.49%
Net profit margin (TTM)
14.52%
Operating margin (TTM)
29.17%
Effective tax rate (TTM)
10.86%
Revenue per employee (TTM)
$669,800
Management effectiveness
Return on assets (TTM)
10.01%
Return on equity (TTM)
33.38%
Valuation
Price to earnings (TTM)
31.812
Price to revenue (TTM)
4.541
Price to book
4.26
Price to tangible book (TTM)
-11.51
Price to free cash flow (TTM)
26.337
Free cash flow yield (TTM)
3.80%
Free cash flow per share (TTM)
1.907
Dividend yield (TTM)
3.52%
Forward dividend yield
3.56%
Growth
Revenue change (TTM)
4.97%
Earnings per share change (TTM)
42.63%
3-year revenue growth (CAGR)
4.22%
10-year revenue growth (CAGR)
2.81%
3-year earnings per share growth (CAGR)
-32.10%
10-year earnings per share growth (CAGR)
65.27%
3-year dividend per share growth (CAGR)
7.01%
10-year dividend per share growth (CAGR)
-3.78%
What the Analysts think about GSK
Analyst ratings (Buy, Hold, Sell) for GSK stock.
Analyst projections of the future price of GSK stock.
Bulls say / Bears say
GSK delivered strong Q2 momentum: Specialty Medicines sales rose 14% at constant exchange rates, including 10% growth in HIV and 17% growth in Oncology, supporting the company’s reaffirmed 2026 guidance. (SEC filing)
Management is accelerating its pipeline, targeting more than 20 Phase III trial starts in 2026 and adding late-stage oncology assets, which could improve the company’s medium-term growth profile. (SEC filing)
A planned $2.5 billion restructuring and cost-saving program could strengthen margins and redirect resources toward new medicines, while management expects 7%–9% growth in 2026 core operating profit and core EPS. (Reuters)
GSK’s growth remains dependent on Specialty Medicines while older respiratory and general-medicine products are weakening; Bloomberg reported that lackluster older respiratory sales overshadowed better-than-expected Q1 earnings. (Bloomberg)
The company faces a significant patent-cliff risk as dolutegravir-based HIV products approach loss of exclusivity between 2028 and 2030, potentially pressuring a major profit engine before replacement products mature. (Reuters)
GSK’s 2026 outlook already assumes vaccines will decline by a low-single-digit percentage to roughly flat, with competitive pressure affecting parts of the portfolio and US Shingrix demand broadly stable. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
GSK Financial Performance
Revenues and expenses
GSK Earnings Performance
Company profitability
Upcoming events
GSK News
AllArticlesVideos
Funds containing GSK
AllGBPEURUSD
Fund name | Fund size | $GSK weighting |
|---|---|---|
Vanguard FTSE 100£VUKE | £4.8B | 2.96% |
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 0.80% |
Vanguard FTSE Developed Europe£VEUA | £2.6B | 0.77% |
Vanguard FTSE Developed Europe€VWCG | €3.1B | 0.69% |
Vanguard FTSE Developed Europe€VEUR | €4.8B | 0.69% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.